Analytics By Light Launches µImager for Real-Time Cell Morphology Monitoring
News related to:Analytics By Light, Inc · 3 min read
PELHAM, NH, UNITED STATES, October 13, 2026 /CourierPR/ -- Analytics By Light, Inc., a new company focused on enhancing biomanufacturing processes, has officially launched with the appointment of Phillip Maderia as its President and CEO. The firm aims to address a critical gap in biomanufacturing by providing continuous, in-situ visibility of cell morphology, a capability currently lacking in conventional process analytical technology.
Maderia, a seasoned biopharmaceutical manufacturing leader with over 35 years of experience, will spearhead the company's efforts. He joins co-founders Dave Kane, who brings four decades of expertise in building electro-optical and medical-device hardware, and J.P. Jiang, the inventor of the µImager’s core imaging approach and quantitative morphology methods.
The µImager™ platform, developed by Analytics By Light, is designed to offer real-time, quantitative morphology sensing for biomanufacturing. Unlike existing technologies that monitor the bioreactor environment, pH, oxygen, and temperature, the µImager™ provides a new layer of information by continuously measuring cell and aggregate morphology in-situ. This capability converts cell diameter, aggregate size, and shape factors into machine-readable process data, enabling real-time signal changes in cell state.
The company is supported by Bloom Bio, a life-sciences commercialization and growth advisory firm, which brings expertise in biomanufacturing and go-to-market strategy.
Early demonstration work is underway with PBS Biotech, and ABL is also partnered with Stellix on joint customer demonstrations. Additionally, the company is engaged with the Advanced Regenerative Manufacturing Institute (ARMI) to present the µImager to ARMI’s regenerative medicine member network.
The µImager platform is initially targeted at the cell therapy market, with a path toward closed-loop and autonomous biomanufacturing. By providing real-time morphology data, the µImager aims to reduce the risk of process deviations and improve overall biomanufacturing efficiency. The platform delivers real-time morphology data for process monitoring, with initial applications in cell therapy and a path toward closed loop and autonomous biomanufacturing.
Analytics By Light, Inc. develops in-situ quantitative morphology sensing for biomanufacturing. The µImager platform delivers real-time morphology data for process monitoring, with initial applications in cell therapy and a path toward closed loop and autonomous biomanufacturing. Learn more at analyticsbylight.com.
The company's mission is to provide a new layer of information by continuously measuring cell and aggregate morphology in-situ, converting cell diameter, aggregate size, and shape factors into machine-readable process data. This capability will enable real-time signal changes in cell state, providing earlier visibility into process-relevant changes and a new input for process decision-making. The µImager platform is bioreactor agnostic, through-wall, and imaging system that can be used in various bioreactor environments.
The company's initial focus is on the cell therapy market, where the µImager can provide critical insights into cell state and morphology. By reducing reliance on episodic sampling and handling, the µImager can also reduce contamination risk. The platform's ability to provide real-time data can help manufacturers steer their processes more effectively, potentially reducing the risk of failed batches and improving overall biomanufacturing efficiency.
Analytics By Light, Inc. is supported by Bloom Bio, a life-sciences commercialization and growth advisory firm, which brings expertise in biomanufacturing and go-to-market strategy.
The company is currently working with PBS Biotech on early demonstration work and is also partnering with Stellix on joint customer demonstrations. Additionally, Analytics By Light is engaged with the Advanced Regenerative Manufacturing Institute (ARMI) to present the µImager to ARMI’s regenerative medicine member network. The µImager platform is designed to provide real-time morphology data for process monitoring, with applications in cell therapy and a path toward closed loop and autonomous biomanufacturing.